A Look at the Year That Was in Biotech

Episode Summary

Executive Summary: Adam Feuerstein reviews biotech's defining 2014 themes: drug pricing pressure sparked by Gilead's Sovaldi and Express Scripts' formulary exclusion, the rise of payer power over specialty-drug pricing, lessons from Dendreon's bankruptcy about manufacturing and business execution, and notable CEOs and companies of the year. He also notes Ebola as a major public-health story with limited long-term investor payoff.

Main Topics: Express Scripts vs. Gilead and the drug-pricing turning point (Priority: 5/5): Feuerstein argues the PBM's decision to exclude Sovaldi in favor of a cheaper competitor marks a potentially tectonic shift: payers are no longer just negotiating discounts, they may now determine which innovative drugs can access the market. Payer power and specialty-drug pricing discipline (Priority: 5/5): The conversation explores how competition, interchangeability, and formulary exclusion could become the main mechanisms controlling prices for specialty medicines, not just traditional market dynamics or congressional pressure. Best and worst biotech CEOs of 2014 (Priority: 3/5): Feuerstein explains that his CEO rankings are based largely on shareholder returns and company performance, noting that acquisitions at high premiums can make executives look brilliant, even if luck plays a role. Agios and Bluebird bio as emblematic new biotech companies (Priority: 4/5): He links the two firms because of shared history, board overlap, and their representation of a new generation of biotech focused on potentially transformative science such as gene therapy and cancer metabolism. Lessons from Dendreon's bankruptcy (Priority: 5/5): Dendreon illustrates that innovation alone is not enough; successful biotech companies also need strong manufacturing, delivery, and cost control, which the company failed to achieve. Ebola, public health urgency, and investor interest (Priority: 4/5): Feuerstein says Ebola drug and vaccine development is likely to continue due to public-health pressure and foundation support, but investor enthusiasm will probably remain short-term and headline-driven.

Key Arguments: Express Scripts' action is more significant than earlier congressional criticism because it comes with actual follow-through and real formulary exclusion. The key question in biotech may shift from 'What will you price your drug at?' to 'What price will PBMs or health plans allow?' Drug pricing pressure will intensify most where there is therapeutic interchangeability and strong competition among equivalent treatments. A successful acquisition can boost a CEO's standing because it delivers strong shareholder returns, though it does not necessarily prove managerial genius. Agios and Bluebird bio symbolize a new era of biotech focused on breakthrough, potentially curative therapies rather than incremental drugs. Dendreon's failure shows that manufacturing, pricing, and distribution economics can determine whether a scientifically innovative product becomes a viable company. Ebola programs will likely get developed because of public-health urgency, but they may not become major long-term profit drivers for investors.

Data Points: Sovaldi annual therapy cost: $84,000 - Referenced as Gilead's price for a course of hepatitis C treatment in the Express Scripts discussion. Express Scripts negotiated price for an alternative hepatitis C therapy: around $51,000 per year - Reported price for the competing therapy favored by Express Scripts over Sovaldi. Sovaldi/Harvoni regimen: one pill taken once a day for 12 weeks - Described as an innovative cure for hepatitis C. Gilead share price move: fell 13% - Mentioned in connection with market reaction to the Express Scripts decision. Podcast structure: Part 1 of a 2-part podcast - The episode is framed as a year-end review with a follow-up planned for the next week. Ebola outbreak: the worst ever seen - Used to emphasize the severity of the 2014 Ebola crisis. Conference date mentioned in sponsorship: October 15th and 16th, 2025 - Referenced in the sponsor read for the Outsourcing and Clinical Trials New England conference.

Pivotal Quotes: "I do kind of see this as potentially a sort of tectonic shift in the biotech industry, and not necessarily in a good way." — Adam Feuerstein: On Express Scripts excluding Sovaldi and the broader significance for drug pricing. "The question now becomes, well, what will PBMs or health plans allow you to price your drug?" — Adam Feuerstein: On how payer power could redefine biotech pricing strategy. "You need more than sort of innovation and a technological advance to become a successful company." — Adam Feuerstein: On the Dendreon bankruptcy and the importance of manufacturing and business execution.

Implications: Biotech investors and executives should expect stronger payer control over pricing, greater scrutiny of business fundamentals beyond science, and less certainty that breakthrough innovation alone will guarantee commercial success.